Astec Lifesciences Ltd.

NSE: ASTEC | BSE: 533138 | ISIN: INE563J01010 | Industry: Agrochemicals
| Weak Stock
683.7500 11.45 (1.70%)
NSE Mar 19, 2025 15:31 PM
Volume: 49,054
 

683.75
1.70%
Motilal Oswal
Revenue grew 12.5% YoY to segment (+22% YoY to INR8.3b). EBITDA margin shrank 60bp YoY to 5.6% 7 May 2019 lower employee cost and other expenses. EBITDA was flat YoY at INR749m 13%/3%/11% YoY to INR58.7b/INR4.6b/INR2.4b. animal feed segment in 4QFY19 drove EBIT margin expansion of 250bp QoQ to 5.5%. GOAGRO is planning for two product launches in the standalone crop protection business. In Astec Lifesciences, it has guided for revenue and EBITDA growth of 15% and 20%, respectively, in FY20. We note that 4Q is a seasonally weak quarter for the palm oil business, wherein GOAGRO reported an EBIT loss of INR1m (v/s a profit of INR40m in 4QFY18) due to higher depreciation and interest cost for its new processing plant. (i) GOAGRO will revisit merger initiation with Astec Lifesciences after a few quarters.
Astec Lifesciences Ltd. has lost -37.16% in the last 3 Months
More from Astec Lifesciences Ltd.
Recommended